|
Steven King has been President and Chief Executive Officer of Peregrine since March 2003. Mr. King started with Peregrine in 1997 as the Director of Research and Development. He first was promoted to Senior Director of Research and Development and then to Vice President of Technology and Product Development. In 2000, Mr. King was also given the responsibility of bringing the company's biologics manufacturing facility into full cGMP compliance and then launching its wholly owned contract manufacturing subsidiary, Avid Bioservices. Since 2001, Mr. King has served as the President and CEO of Avid Bioservices, and was promoted to Peregrine's Chief Operating Officer at that time. Prior to joining Peregrine, Mr. King was employed at a corporation that was developing Vascular Targeting Agents (VTA), which was acquired by Peregrine in 1997. Mr. King previously worked with Dr. Philip Thorpe, inventor of the VTA technology, at the University of Texas Southwestern Medical Center at Dallas and is a co-inventor on over 25 U.S. and foreign patents and patent applications in the VTA area. Mr. King holds BS and MS degrees in Biology from Texas Tech University. | 